This page shows the latest Monsanto news and features for those working in and with pharma, biotech and healthcare.
The shake-up – which follows its $66bn takeover of agricultural products company Monsanto – will also result in the sale of its animal health division to narrow its focus to pharma, consumer ... and agility.” He also insisted that the moves have
group Monsanto - which it now expects to complete before June - won’t derail its other business units.
Moeller is taking over the R&D helm at a pivotal point for Bayer, which has been in the throes of a mega-merger with Monsanto - finalised today - while also working
PAH) therapy Adempas (riociguat) - that Bayer needs to drive its pharma unit as it digests Monsanto - bought for $66bn last September.
US of Bayer’s $66bn acquisition of agri-business firm Monsanto.
Monsanto acquisition 'won't curtail pharma deals'. Overall, group sales rise 1.5% to 46.8bn in 2016, in a year that saw Bayer agree in September a $66bn deal to ... and that the company's long-term funding plans would not be impacted by the Monsanto deal.
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
This was its position in the recent Dow/ DuPont and Bayer/Monsanto mergers, where the Commission found that each transaction would have ‘significantly reduced competition in a number of markets’ and
He has also served as a group leader at Monsanto Co, a senior staff fellow at the National Institutes of Health and as an assistant professor at the University of Maryland.
In the same vein, focusing its interests, Bayer put in a $62bn opening bid [$122 per share] to purchase Monsanto, which bid has been rejected as insufficient.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Reinsdorf, who has a background in corporate governance and expertise in managing corporate and legal affairs, has served in various positions for companies including Tyco International and Monsanto.
Shailubhai has also previously served at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).
Monsanto, MSD and Danone.
The choice is a change of direction for Rapp, who was most recently mergers and acquisitions lead for the chemical firm Monsanto Company and has served as CEO of the
His prior experience includes roles at Tanox, Biogen and Monsanto Life Sciences.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...